Ruti Aga's Six-Year Ban: How a Forged Prescription Turned a Two-Year Case Into a Career Ending

I don't have a press-conference recording. I have a document — the Athletics Integrity Unit (AIU) statement issued on Thursday, in which two numbers were placed side by side: two years, and four years. Add them. Six. Ethiopian marathoner Ruti Aga, thirty-two years old, suspended for six years from 10 September. Before that sentence was finished, my calendar was already running — thirty-two plus six is thirty-eight. In the depth of Ethiopian women's marathon running, a thirty-eight-year-old has no place, especially with an anti-doping entry on her file.

I stopped the first draft. Because there was one more thing in the file that had arrived not in the language of the statement but in the language of the news copy — 'prohibited steroid'. This was wrong. And this misreading is now so widespread that had I let it pass quietly, the very identity of this case would have changed. I knew I had to fix the word before I wrote the report, because the whole case rests on this — the class of the substance, not any story of 'doping'.

This is not a doping case; it is a document-forgery case. And that distinction is what fixes its real severity.

---

Context: The start list first, the story after

Having spent twenty-six years on the sports desk in Chennai, I read athletics the way a meet official reads a start list — entry marks first, sentiment later, and the verdict only at the very end. So before opening Ruti Aga's file, I did what I have done for twenty years: I looked at her Tokyo entry.

The 2026 Tokyo Marathon. She won it — 2:20:40. Before that, Berlin 2026, second place, approximately 2:18:34. And three consecutive second places at major races across Asia and Europe — three World Marathon Majors silver medals. This is not built by accident. A runner who wins Tokyo and finishes second in Berlin is counted among the ten best women's marathoners in the world. That is her real legacy — and it is written nowhere in the statement, which is itself a signal.

To understand the depth of Ethiopian women's marathon running, one comparison is necessary. When a country has a sub-2:12 woman, then a runner with 2:18-2:20 capacity is not automatically safe in selection terms. This is the reality of both Ethiopia and Kenya. Both pools are extremely deep, and both are structurally highly vulnerable to weaknesses in entourage-level governance.

So when a thirty-two-year-old runner with no world championship medal leaves the sport, nothing changes in the national selection arithmetic. This is the harshest fact of the case: the competition is unaffected; only the governance system is affected.

But my attention is still stuck on that first draft — 'prohibited steroid'. This is where the real case begins.

---

Core: The classification of the substance — and the error that distorted the entire debate

Media reports called methylprednisolone a 'prohibited steroid' and said WADA classifies it as 'performance enhancing'. From my experience, this is the kind of imprecision that changes the reading of an entire story — like calling a goal a half-time in a match report.

Methylprednisolone is a glucocorticoid — class S9 of the WADA Prohibited List. It is not an anabolic steroid (S1). The gap between the two is the gap between earth and sky, and that gap is not merely one of pharmacological vocabulary but of legal consequence.

Under the current List, S9 glucocorticoids are prohibited in-competition only — and only by injection, oral or rectal routes.

The direct implication is that a therapeutic steroid injection in the knee, entirely legal out of competition, becomes a violation only if residues are found in a sample taken in competition. That is, the whole case rests not on 'steroid use' but on the route of administration and its timing relative to the competition.

There is a fine point in road-race rules that very few know. In road racing, the testing window opens at 23:59 the day before the race. So if someone takes a glucocorticoid injection some days before a race and does not observe the proper washout period, the sample will catch it — even if the intent was never performance enhancement. This is a technical trap, and it frequently proves fatal for marathoners.

Now read the two numbers of the statement again against this background.

Presence of a prohibited substance — two years. This conforms to the category WADA calls a 'Specified Substance', where even without proven intent the standard sanction is two years. And then the tampering violation — four years. This is the Code's standard tampering sanction.

The sum is clear: two plus four makes six. And this arithmetic tells us what the statement does not say directly — the panel rejected the 'no significant fault' mitigation.

This is the point at which the entire case turns. Because had the athlete possessed genuine medical records — a documented knee injury, a registered physician, an authentic prescription — then, given the in-competition-only nature of the S9 class, a legitimate path of defence was open. An argument on timing, route and medical necessity was possible. The tampering charge might never have arrived at all.

But the prescription was forged. And in that instant, the only defence that could have worked was destroyed.

It bears repeating, because this is the central paradox of the whole affair: the substance was not what she was punished for — the document was.

---

The chain of the forged prescription: three independent verification failures

According to the statement, Aga explained her use of methylprednisolone by citing a knee injury. The problem was that the clinic from which the prescription was issued did not exist at all. The person who wrote the prescription had no medical registration — he was a family member. And when the investigation proceeded, that person claimed he had used 'an old prescription pad left over from a former workplace'. That clinic, whose pad it was claimed to be, publicly rejected the claim outright.

Three separate verification failures. No clinic on the paper, no registration for the signatory on the paper, and the denial of the very institution whose name was printed on it. This is not a filing error. These are the signals of an athlete operating without a credentialed team physician.

I must lodge an interruption here, because keeping the limits of the file clear is my habit. The statement does not say in which year the China race took place in March, nor in which year the six-year ban will end. There is a provisional suspension from 10 September, and the statement came on Thursday — this suggests the current year, but that is inference, not fact. I record it as inference.

One more thing that is not in the statement but emerges from reasoning: the March race in China in which her sample was collected was almost certainly a World Athletics Label road race with a strong women's elite field and both out-of-competition and in-competition testing. Otherwise no AIU test would exist at all. And under standard AIU procedure, her result and prize money from that race must also be treated as annulled, although the statement does not say so explicitly.

Now another paradox, which I am noting separately in my notebook. The panel found the presence violation proven but did not aggravate it — that is, it did not lay a heavy charge regarding intent. But it held the tampering fully culpable. This is almost contradictory, because a forged document is itself circumstantial evidence of concealment intent — yet it did not escalate the presence sanction. The panel kept them in separate boxes. This is technical jurisprudence, and it needs to be understood properly.

Counting the sanction back to 10 September is not a concession. Time under provisional suspension counts toward the ban — in real terms the athlete gains nothing.

---

The athlete's condition: when the knee is the root of the case, and the document its consequence

Chronic knee trouble in marathoners is a well-recognised failure mode — high-volume training and the load of repeated races. The statement cites a knee injury as the reason for the treatment.

For me the important fact is that intra-articular or peri-articular methylprednisolone for a knee problem is standard sports-medicine practice in distance runners. It is medically credible. And precisely that credibility makes the forged prescription more devastating. Because if the treatment had genuinely occurred, it could have been proven with real records.

Here I must clarify one thing, because I do not wish to deceive my readers. The knee problem was probably chronic, career-long — not merely an acute March event. The reason is that when a runner attempts to fabricate a paper trail, it is often not a single lapse but a symptom of a repeated pattern of informal treatment. This is my inference, of medium confidence, and I record it as such.

Return to the arithmetic of age. Thirty-two. A six-year ban. A return age of roughly thirty-eight. In the depth of Ethiopian women's marathon running, a thirty-eight-year-old with an anti-doping record is practically unselectable. In this sense the ban is functionally a lifetime one for elite purposes.

And here a question arises that I asked by stepping outside the file — did any agent or manager know of or accept this forged document? The AIU statement names only the family member. Whether the agent or management was investigated is unknown. This is my low-to-medium confidence inference, and I record it not as an accusation but only as an empty space that no one is filling.

---

Structure: the money of road racing and the testing of road racing are colliding in the same place

I have watched Asia's label-race circuit for two decades. This circuit functions as an attractive, low-risk income tier for East African marathoners — in the interval between Majors. Large appearance fees, strong elite fields, favourable weather. For a 2:18-2:20 runner, a mix of selective Major races and Asian label races is a rational economic strategy.

But that same tier has now become the AIU's most productive testing ground. The appearance-fee economy and the testing economy are now colliding in the very same races. This is the part of the case that found no place in the news, but which will explain many future cases.

In this context Aga's case is not an isolated incident. It belongs to a recognisable family in which the first substance violation in East African road-running cases is often attached to a fabricated or altered explanation. This builds a larger picture of governance: the enforcement frontier has shifted from 'detection' to 'document verification'.

This is my medium-confidence inference, drawn from case clustering.

One more thing I will state plainly. China's label-race circuit is now a high-scrutiny zone. The intersection of large appearance-fee budgets, deep East African elite fields, and AIU testing means that results from this tier will increasingly arrive with a rising integrity risk.

---

Rules and standards: was a defence possible?

Now the question that troubles me most, because it applies to every runner passing through a knee problem.

Suppose a runner takes a methylprednisolone injection in the knee some days before a competition. Out of competition this is entirely legal. The route is legitimate too. With a credentialed physician, a recorded medical file, and a real track of treatment — this is a wholly blameless procedure.

The problem arises in only one thing: failure to observe the washout period. If the necessary time between administration of the glucocorticoid and the competition is not observed, the sample will come back positive. This is a technical trap whose knowledge is routine for runners with proper athlete support systems, and fatal for runners with informal arrangements.

In Aga's case, the most rational path of defence was this: medical records, a real prescription, an explanation of timing relative to the competition, and perhaps an argument of medical necessity. Had all this been assembled, the presence charge would either have been greatly reduced, or could have reached the level of 'no fault' — perhaps a formal reprimand, or a substantially reduced period. And the tampering charge would likely never have arrived.

The best case (which was possible) was simple: a TUE-consistent treatment plan and correct washout timing. Then there would have been no case at all.

I am not writing this as a moral sermon. I am writing it as a ledger entry, because my habit is to see which line in the file came from which document. In this case, all three lines — clinic, signatory, prescription pad — came from the same place. They all break at the same point.

There is one more dimension that should not be left out, though its investigation lies outside the AIU's jurisdiction: document forgery may be a criminal offence. The statement does not mention referral to national authorities. This is an open space, and I record it as an open space, not as an accusation.

---

The contrarian angle: this is not a doping story, it is a medical-governance story

Now the part the media did not write.

If this case is read through the frame of 'the runner doped and was caught', it is an ordinary news item. But if you read it through the frame in which the case actually occurred, it becomes a completely different story.

Aga received a six-year ban for a substance with no proven endurance benefit, and not for the use of that substance, but for the paper built around it.

This is an uncomfortable fact, and I will not soften it. On one hand, it is evidence of the AIU's rigour and procedural severity. Regardless of the type of substance, a harsh sanction was imposed for documentary tampering. This is the picture of rule-based enforcement.

On the other hand, it is also the fact that will be cited in the debate over proportionality — six years for a glucocorticoid, when in many cases even proven use of anabolic steroids draws four years. I am not taking sides in this debate — I am only pointing to the fact that ought to be on record.

But the real paradox is elsewhere, and it stings me most.

This case shows that the rule-net is now at a level where technical ignorance is as fatal as intent. A runner who had received proper medical advice, who had a registered physician, and who knew the washout period — could have escaped this entire case. But she forged a prescription, which means she knew her treatment was procedurally problematic. That is, she possessed part of the knowledge — only half.

This is the point at which the story turns from individual failure into systemic failure. Informal medical networks serve many runners in East African road-running training groups. One runner's forged prescription is not an isolated incident but a symptom of a system lacking basic infrastructure like a credentialed team physician.

If this is true — and I record it as a medium-confidence inference — then the real lesson of this case is not that 'those who dope get caught'. The real lesson is that in a system where an athlete's medical care is in informal hands, the documents eventually break — and that break fractures the runner's career.

I would also want to see whether any agent's or management's role was investigated in this case. Only a family member is named. Did management accept or encourage the document? This is an empty space I deliberately do not fill — because I have rules, and one of them is: the accusation does not go in the same dispatch as the raw result.

---

The debate not written in the file

I must open one more layer, because a debate has been running for years over East African road-running cases, and the six-year sanction in this affair will give that debate fresh force.

The question is: is enforcement uniform? Does the same kind of violation draw the same kind of sanction, whether the runner comes from a wealthy federation system or from an informal training group?

I deliberately withhold judgment on this question. The reason is that I do not have comparative data that could answer it. But I can say this much: when a runner in one system has a credentialed team doctor, that same runner keeps a record of the glucocorticoid injection, knows the washout period, and never gets into trouble. And when a runner lacks this architecture, the same injection ends her career. This is not an inequality of sanction — it is an inequality of structure. But the outcome is the same: one career survives, the other does not.

And this is the point at which I want to ask my readers a question: should we read this sanction as the failure of that runner, or of the system in which the person who treated her came from the family, and the prescription from a drawer?

I will not answer it. I will only say that a runner who races under the pressure of injury — to protect appearance-fee income, to keep sponsorship — and for whom the cheapest remedy is a glucocorticoid, and around whom the medical apparatus is informal, will fall into this trap again and again. Aga's forged prescription is the consequence of that trap, not its cause.

---

The tape is a witness: the arithmetic, and what the statement does not say

I read the whole file again, because my habit is to write the verdict last.

What is proven: a six-year ban. From 10 September. Two years for presence, four for tampering. The substance methylprednisolone, class S9, prohibited in-competition only. A positive sample after winning a half marathon in China in March. A knee injury cited. A prescription from a clinic that does not exist, from a person not registered, on a pad disowned by its original clinic.

What is not in the statement but is almost certain: the result and prize money from the March race annulled. Any ranking points thereafter expunged. A possible criminal referral that goes unmentioned. And a CAS appeal window, typically open for roughly twenty-one days from the reasoned decision.

What is blank: the year of the March race. The year-date of the ban's expiry. No mark, no split, no field strength for the race. No mention of an agent or management investigation. No official statement from the Ethiopian federation.

I do not fill these blanks. This is my method — and it is also the greatest strength of this case. Where the file has a hole, I write hole, not brick.

And if I had to name the whole affair in one line, it would be this: it is a sanction given not for a substance but for a document — and she made that document because she had no other document.

---

What to watch: the variables ahead

Now I return to the printed list and record what should be watched over the next few months.

First variable — the CAS appeal. Will Aga appeal, and can she challenge the tampering finding? That finding is document-based, and document-based findings are hard to overturn — but not impossible, if it is proven that she did not fabricate the prescription but was handed a fabricated one. The difference between the two is whether she had tampering intent — and that difference is four years.

Second variable — the scope of annulment. Will the March race result and prize money be formally withdrawn? And does any result before March take a hit? Since the violation is anchored to the March race, and no finding of prior use emerged, the 2026 Tokyo title — and the three Major silvers — should stand on the record. I say this explicitly because I want it written down, even if later news blurs it.

Third variable — the Ethiopian federation's silence. There is nothing from the federation in the statement. This is not unusual, but it is a signal. It remains to be seen whether the federation takes any position, and if so, whether it is on the runner's side.

Fourth variable — and for me the most important — does this case give birth to any systemic change? Do the AIU or World Athletics take a broader position on the issue of informal medical networks, or does the case close as an individual sanction? If it is the latter, then several similar cases will arrive over the next few years — and each time the sanction will fall on the runner, not on the system that produced her.

I keep a ledger in which every layer is recorded. In this case, the ledger told me there are three things — a substance, a prescription, and a knee. The substance was class S9 and opened a real path of legal defence. The prescription closes that path. And the knee is the root at which no one is looking.

An empty stadium audits every assumption the crowd used to hide. Here there was a crowd — an athlete, a family, a medical apparatus whose clinic did not exist, a prescription whose pad did not exist. And when the Athletics Integrity Unit issued that statement, the assumption broke. What remained? A Tokyo title, three Major silvers, and a young career that will never begin again at thirty-eight.

The next file will probably belong to another runner. In that file, next time, I would like to see who wrote about the knee, and when — because this time, the prescription was on the same page of the same document that carried the career away.